These data revealed that the CDK4/6 inhibitor abolished the effects of GLI1 overexpression on AML cell proliferation and combined use of GANT61 and PD 0332991 enhances Ara-c drug sensitivity. The gene discussed is CDK4; the disease is acute myeloid leukemia.